|
US975286A
(en)
*
|
1910-03-05 |
1910-11-08 |
Charles H A F L Ross |
Trigger mechanism.
|
|
GB835638A
(en)
|
1956-12-01 |
1960-05-25 |
Novo Terapeutisk Labor As |
Insulin crystal suspensions having a protracted effect
|
|
GB840870A
(en)
|
1957-08-03 |
1960-07-13 |
Novo Terapeutisk Labor As |
Improvements in or relating to insulin preparations
|
|
US3758683A
(en)
|
1971-04-30 |
1973-09-11 |
R Jackson |
Insulin product
|
|
US3868358A
(en)
|
1971-04-30 |
1975-02-25 |
Lilly Co Eli |
Protamine-insulin product
|
|
US4153689A
(en)
|
1975-06-13 |
1979-05-08 |
Takeda Chemical Industries, Ltd. |
Stable insulin preparation for nasal administration
|
|
GB1554157A
(en)
|
1975-06-13 |
1979-10-17 |
Takeda Chemical Industries Ltd |
Stable insulin preparation for intra nasal administration
|
|
GB1527605A
(en)
|
1975-08-20 |
1978-10-04 |
Takeda Chemical Industries Ltd |
Insulin preparation for intranasal administration
|
|
US4165370A
(en)
|
1976-05-21 |
1979-08-21 |
Coval M L |
Injectable gamma globulin
|
|
JPS6033474B2
(ja)
|
1978-05-11 |
1985-08-02 |
藤沢薬品工業株式会社 |
新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
|
|
US4783441A
(en)
|
1979-04-30 |
1988-11-08 |
Hoechst Aktiengesellschaft |
Aqueous protein solutions stable to denaturation
|
|
EP0018609B1
(de)
|
1979-04-30 |
1983-09-21 |
Hoechst Aktiengesellschaft |
Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
|
|
JPS55153712A
(en)
|
1979-05-18 |
1980-11-29 |
Kao Corp |
Insulin pharmaceutical preparation and its production
|
|
DE3033127A1
(de)
|
1980-09-03 |
1982-04-08 |
Hoechst Ag, 6000 Frankfurt |
Neue analoga des insulins
|
|
US4367737A
(en)
|
1981-04-06 |
1983-01-11 |
George Kozam |
Multiple barrel syringe
|
|
EP0083619A1
(en)
|
1981-07-17 |
1983-07-20 |
Nordisk Insulinlaboratorium |
A stable aqueous, therapeutic insulin preparation and a process for preparing it
|
|
NL193099C
(nl)
|
1981-10-30 |
1998-11-03 |
Novo Industri As |
Gestabiliseerde insuline-oplossing.
|
|
DE3326473A1
(de)
|
1983-07-22 |
1985-01-31 |
Hoechst Ag, 6230 Frankfurt |
Pharmazeutisches mittel zur behandlung des diabetes mellitus
|
|
DE3326472A1
(de)
|
1983-07-22 |
1985-02-14 |
Hoechst Ag, 6230 Frankfurt |
Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
|
|
DE3327709A1
(de)
|
1983-07-29 |
1985-02-07 |
Hoechst Ag, 6230 Frankfurt |
Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
|
|
DE3333640A1
(de)
|
1983-09-17 |
1985-04-25 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
|
|
CA1244347A
(en)
|
1984-05-29 |
1988-11-08 |
Eddie H. Massey |
Stabilized insulin formulations
|
|
US4839341A
(en)
|
1984-05-29 |
1989-06-13 |
Eli Lilly And Company |
Stabilized insulin formulations
|
|
DE3576120D1
(de)
|
1984-06-09 |
1990-04-05 |
Hoechst Ag |
Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung.
|
|
DE3440988A1
(de)
|
1984-11-09 |
1986-07-10 |
Hoechst Ag, 6230 Frankfurt |
Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
|
|
DK347086D0
(da)
|
1986-07-21 |
1986-07-21 |
Novo Industri As |
Novel peptides
|
|
US5008241A
(en)
|
1985-03-12 |
1991-04-16 |
Novo Nordisk A/S |
Novel insulin peptides
|
|
DK113585D0
(da)
|
1985-03-12 |
1985-03-12 |
Novo Industri As |
Nye peptider
|
|
IL78425A
(en)
|
1985-04-15 |
1991-05-12 |
Lilly Co Eli |
Intranasal formulation containing insulin
|
|
US4689042A
(en)
|
1985-05-20 |
1987-08-25 |
Survival Technology, Inc. |
Automatic medicament ingredient mixing and injecting apparatus
|
|
DE3526995A1
(de)
|
1985-07-27 |
1987-02-05 |
Hoechst Ag |
Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
|
|
PH25772A
(en)
|
1985-08-30 |
1991-10-18 |
Novo Industri As |
Insulin analogues, process for their preparation
|
|
US4960702A
(en)
|
1985-09-06 |
1990-10-02 |
Codon |
Methods for recovery of tissue plasminogen activator
|
|
US5496924A
(en)
|
1985-11-27 |
1996-03-05 |
Hoechst Aktiengesellschaft |
Fusion protein comprising an interleukin-2 fragment ballast portion
|
|
DE3636903A1
(de)
|
1985-12-21 |
1987-07-02 |
Hoechst Ag |
Fusionsproteine mit eukaryotischem ballastanteil
|
|
DE3541856A1
(de)
|
1985-11-27 |
1987-06-04 |
Hoechst Ag |
Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
|
|
CA1275922C
(en)
|
1985-11-28 |
1990-11-06 |
Harunobu Amagase |
Treatment of cancer
|
|
DE3544295A1
(de)
|
1985-12-14 |
1987-06-19 |
Bayer Ag |
Thermoplastische formmassen mit hoher kriechstromfestigkeit
|
|
US5614492A
(en)
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
|
PH23446A
(en)
|
1986-10-20 |
1989-08-07 |
Novo Industri As |
Peptide preparations
|
|
PT86819B
(pt)
|
1987-02-25 |
1992-05-29 |
Novo Industri As |
Processo para a preparacao de novos derivados da insulina e de composicoes farmaceuticas que os contem
|
|
US5034415A
(en)
|
1987-08-07 |
1991-07-23 |
Century Laboratories, Inc. |
Treatment of diabetes mellitus
|
|
DE3726655A1
(de)
|
1987-08-11 |
1989-02-23 |
Hoechst Ag |
Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
|
|
DK257988D0
(da)
|
1988-05-11 |
1988-05-11 |
Novo Industri As |
Nye peptider
|
|
US6875589B1
(en)
|
1988-06-23 |
2005-04-05 |
Hoechst Aktiengesellschaft |
Mini-proinsulin, its preparation and use
|
|
DE3827533A1
(de)
|
1988-08-13 |
1990-02-15 |
Hoechst Ag |
Pharmazeutische zubereitung zur behandlung des diabetes mellitus
|
|
US4923162A
(en)
|
1988-09-19 |
1990-05-08 |
Fleming Matthew C |
Radiation shield swivel mount
|
|
DE3837825A1
(de)
|
1988-11-08 |
1990-05-10 |
Hoechst Ag |
Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
|
|
US5225323A
(en)
|
1988-11-21 |
1993-07-06 |
Baylor College Of Medicine |
Human high-affinity neurotransmitter uptake system
|
|
FI913037A7
(fi)
|
1988-12-23 |
1991-06-20 |
Novo Nordisk As |
Ihmisen insuliinianalogit
|
|
US4994439A
(en)
|
1989-01-19 |
1991-02-19 |
California Biotechnology Inc. |
Transmembrane formulations for drug administration
|
|
NZ232375A
(en)
|
1989-02-09 |
1992-04-28 |
Lilly Co Eli |
Insulin analogues modified at b29
|
|
US5514646A
(en)
|
1989-02-09 |
1996-05-07 |
Chance; Ronald E. |
Insulin analogs modified at position 29 of the B chain
|
|
DK134189D0
(da)
|
1989-03-20 |
1989-03-20 |
Nordisk Gentofte |
Insulinforbindelser
|
|
WO1990013361A1
(en)
|
1989-05-04 |
1990-11-15 |
Southern Research Institute |
Improved encapsulation process and products therefrom
|
|
US5358857A
(en)
|
1989-08-29 |
1994-10-25 |
The General Hospital Corp. |
Method of preparing fusion proteins
|
|
IL95495A
(en)
|
1989-08-29 |
1996-10-16 |
Hoechst Ag |
Fusion proteins their preparation and use
|
|
US5227293A
(en)
|
1989-08-29 |
1993-07-13 |
The General Hospital Corporation |
Fusion proteins, their preparation and use
|
|
US5545618A
(en)
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
|
CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
|
US5397771A
(en)
|
1990-05-10 |
1995-03-14 |
Bechgaard International Research And Development A/S |
Pharmaceutical preparation
|
|
EP0532546B1
(en)
|
1990-05-10 |
1998-03-18 |
Bechgaard International Research And Development A/S |
A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
|
|
DK155690D0
(da)
|
1990-06-28 |
1990-06-28 |
Novo Nordisk As |
Nye peptider
|
|
DK10191D0
(da)
|
1991-01-22 |
1991-01-22 |
Novo Nordisk As |
Hidtil ukendte peptider
|
|
US5272135A
(en)
|
1991-03-01 |
1993-12-21 |
Chiron Ophthalmics, Inc. |
Method for the stabilization of methionine-containing polypeptides
|
|
CA2038597A1
(en)
|
1991-03-19 |
1992-09-20 |
Jose P. Garzaran |
A method and a pharmaceutical preparation for treating pain
|
|
US6468959B1
(en)
|
1991-12-05 |
2002-10-22 |
Alfatec-Pharm Gmbh |
Peroral dosage form for peptide containing medicaments, in particular insulin
|
|
US5614219A
(en)
|
1991-12-05 |
1997-03-25 |
Alfatec-Pharma Gmbh |
Oral administration form for peptide pharmaceutical substances, in particular insulin
|
|
US5197926A
(en)
|
1992-02-18 |
1993-03-30 |
Hedstrom Corporation |
Swing connection guard
|
|
CH682806A5
(de)
|
1992-02-21 |
1993-11-30 |
Medimpex Ets |
Injektionsgerät.
|
|
CH682805A5
(de)
|
1992-02-24 |
1993-11-30 |
Medimpex Ets |
Anzeigeeinrichtung für ein Injektionsgerät.
|
|
DK36392D0
(da)
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
|
US5846747A
(en)
|
1992-03-25 |
1998-12-08 |
Novo Nordisk A/S |
Method for detecting glucagon-like peptide-1 antagonists and agonists
|
|
DK39892D0
(da)
|
1992-03-25 |
1992-03-25 |
Bernard Thorens |
Peptid
|
|
US5253785A
(en)
|
1992-04-02 |
1993-10-19 |
Habley Medical Technology Corp. |
Variable proportion dispenser
|
|
DK0600372T3
(da)
|
1992-12-02 |
1997-08-11 |
Hoechst Ag |
Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer.
|
|
CZ158895A3
(en)
|
1992-12-18 |
1995-12-13 |
Lilly Co Eli |
Insulin analog, process of its preparation and pharmaceutical composition containing thereof
|
|
US5358708A
(en)
|
1993-01-29 |
1994-10-25 |
Schering Corporation |
Stabilization of protein formulations
|
|
US5478323A
(en)
|
1993-04-02 |
1995-12-26 |
Eli Lilly And Company |
Manifold for injection apparatus
|
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
|
DE10199011I2
(de)
|
1993-06-21 |
2004-10-14 |
Novo Nordisk As |
ASP-B28-Insulinkristalle.
|
|
WO1996007399A1
(en)
|
1994-09-09 |
1996-03-14 |
Takeda Chemical Industries, Ltd. |
Sustained release preparation containing metal salt of a peptide
|
|
US5506203C1
(en)
|
1993-06-24 |
2001-02-06 |
Astra Ab |
Systemic administration of a therapeutic preparation
|
|
US5534488A
(en)
|
1993-08-13 |
1996-07-09 |
Eli Lilly And Company |
Insulin formulation
|
|
EP0998917A1
(en)
|
1993-11-19 |
2000-05-10 |
Alkermes Controlled Therapeutics Inc. II |
Preparation of biodegradable microparticles containing a biologically active agent
|
|
US5705483A
(en)
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
|
IT1265271B1
(it)
|
1993-12-14 |
1996-10-31 |
Alcatel Italia |
Sistema di predistorsione in banda base per la linearizzazione adattativa di amplificatori di potenza
|
|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
DE4405179A1
(de)
|
1994-02-18 |
1995-08-24 |
Hoechst Ag |
Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
|
|
DE4405388A1
(de)
|
1994-02-19 |
1995-08-24 |
Hoechst Ag |
Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
|
|
HUT75676A
(en)
|
1994-03-07 |
1997-05-28 |
Inhale Therapeutic Syst |
Methods and compositions for pulmonary delivery of insulin
|
|
US5474978A
(en)
|
1994-06-16 |
1995-12-12 |
Eli Lilly And Company |
Insulin analog formulations
|
|
US5559094A
(en)
|
1994-08-02 |
1996-09-24 |
Eli Lilly And Company |
AspB1 insulin analogs
|
|
US5879584A
(en)
|
1994-09-10 |
1999-03-09 |
The Procter & Gamble Company |
Process for manufacturing aqueous compositions comprising peracids
|
|
US5547929A
(en)
|
1994-09-12 |
1996-08-20 |
Eli Lilly And Company |
Insulin analog formulations
|
|
US5766582A
(en)
|
1994-10-11 |
1998-06-16 |
Schering Corporation |
Stable, aqueous alfa interferon solution formulations
|
|
US5707641A
(en)
|
1994-10-13 |
1998-01-13 |
Pharmaderm Research & Development Ltd. |
Formulations comprising therapeutically-active proteins or polypeptides
|
|
AR002976A1
(es)
|
1995-03-31 |
1998-05-27 |
Lilly Co Eli |
Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
|
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
AU5724996A
(en)
|
1995-05-05 |
1996-11-21 |
Eli Lilly And Company |
Single chain insulin with high bioactivity
|
|
US5824638A
(en)
|
1995-05-22 |
1998-10-20 |
Shire Laboratories, Inc. |
Oral insulin delivery
|
|
US6143718A
(en)
|
1995-06-07 |
2000-11-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of Type II diabetes mellutis with amylin agonists
|
|
EP0831922A2
(en)
|
1995-06-08 |
1998-04-01 |
Therexsys Limited |
Improved pharmaceutical compositions for gene therapy
|
|
AU6242096A
(en)
|
1995-06-27 |
1997-01-30 |
Takeda Chemical Industries Ltd. |
Method of producing sustained-release preparation
|
|
JPH11292787A
(ja)
|
1995-08-15 |
1999-10-26 |
Asahi Chem Ind Co Ltd |
生理活性ペプチドを含有する経粘膜投与製剤
|
|
DE19545257A1
(de)
|
1995-11-24 |
1997-06-19 |
Schering Ag |
Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
|
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
|
DE19637230A1
(de)
|
1996-09-13 |
1998-03-19 |
Boehringer Mannheim Gmbh |
Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
|
|
KR100600457B1
(ko)
|
1996-06-05 |
2006-07-13 |
로셰 디아그노스틱스 게엠베하 |
엑센딘 유사체, 이의 제조방법 및 이를 함유한 약제
|
|
IL127366A0
(en)
|
1996-06-20 |
1999-10-28 |
Novo Nordisk As |
Insulin preparations containing NaCl
|
|
IL127365A0
(en)
|
1996-06-20 |
1999-10-28 |
Novo Nordisk As |
Insulin preparations containing carbohydrates
|
|
US5948751A
(en)
|
1996-06-20 |
1999-09-07 |
Novo Nordisk A/S |
X14-mannitol
|
|
US6110703A
(en)
|
1996-07-05 |
2000-08-29 |
Novo Nordisk A/S |
Method for the production of polypeptides
|
|
ES2319936T5
(es)
|
1996-08-08 |
2013-06-24 |
Amylin Pharmaceuticals, Inc. |
Regulación de la motilidad gastrointestinal
|
|
US5783556A
(en)
|
1996-08-13 |
1998-07-21 |
Genentech, Inc. |
Formulated insulin-containing composition
|
|
AU752411B2
(en)
|
1996-08-13 |
2002-09-19 |
Genentech Inc. |
Formulation
|
|
ATE356830T1
(de)
|
1996-08-30 |
2007-04-15 |
Novo Nordisk As |
Glp-1 derivate
|
|
US6006753A
(en)
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
|
US6277819B1
(en)
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
|
EP1629849B2
(en)
|
1997-01-07 |
2017-10-04 |
Amylin Pharmaceuticals, LLC |
Pharmaceutical compositions comprising exendins and agonists thereof
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
WO1998035033A1
(en)
|
1997-02-05 |
1998-08-13 |
1149336 Ontario Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
US5846937A
(en)
|
1997-03-03 |
1998-12-08 |
1149336 Ontario Inc. |
Method of using exendin and GLP-1 to affect the central nervous system
|
|
US6043214A
(en)
|
1997-03-20 |
2000-03-28 |
Novo Nordisk A/S |
Method for producing powder formulation comprising an insulin
|
|
CA2283705A1
(en)
|
1997-03-20 |
1998-10-01 |
Novo Nordisk A/S |
Zinc free insulin crystals for use in pulmonary compositions
|
|
US6310038B1
(en)
|
1997-03-20 |
2001-10-30 |
Novo Nordisk A/S |
Pulmonary insulin crystals
|
|
AR012894A1
(es)
|
1997-06-13 |
2000-11-22 |
Lilly Co Eli |
Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
|
|
JP3919235B2
(ja)
|
1997-06-13 |
2007-05-23 |
ジェネンテク，インコーポレイテッド |
抗体製剤
|
|
DE19726167B4
(de)
|
1997-06-20 |
2008-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
|
|
AU749914B2
(en)
|
1997-08-08 |
2002-07-04 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
DE19735711C2
(de)
|
1997-08-18 |
2001-04-26 |
Aventis Pharma Gmbh |
Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
|
|
PL340255A1
(en)
|
1997-10-24 |
2001-01-29 |
Lilly Co Eli |
Non-dissolving insulin compositions
|
|
US6444641B1
(en)
|
1997-10-24 |
2002-09-03 |
Eli Lilly Company |
Fatty acid-acylated insulin analogs
|
|
ZA989744B
(en)
|
1997-10-31 |
2000-04-26 |
Lilly Co Eli |
Method for administering acylated insulin.
|
|
WO1999024071A1
(en)
|
1997-11-12 |
1999-05-20 |
Alza Corporation |
Method for decreasing self-association of polypeptides
|
|
BR9815670A
(pt)
|
1997-11-14 |
2000-10-17 |
Amylin Pharmaceuticals Inc |
Compostos agonistas de exendina
|
|
AU756836B2
(en)
|
1997-11-14 |
2003-01-23 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
CA2312190A1
(en)
|
1997-12-05 |
1999-06-17 |
Eli Lilly And Company |
Glp-1 formulations
|
|
WO1999034821A1
(en)
|
1998-01-09 |
1999-07-15 |
Novo Nordisk A/S |
Stabilised insulin compositions
|
|
ES2291017T3
(es)
|
1998-02-13 |
2008-02-16 |
Amylin Pharmaceuticals, Inc. |
Efectos inotropicos y diureticos de la exendina y glp-1.
|
|
BR9908178A
(pt)
|
1998-02-23 |
2002-01-15 |
Neurocrine Biosciences Inc |
Processos para tratamento de diabetes usando análogos peptìdios de insulina
|
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
AU757658B2
(en)
|
1998-03-09 |
2003-02-27 |
Zealand Pharma A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
DE69918070T2
(de)
|
1998-03-13 |
2005-08-25 |
Novo Nordisk A/S |
Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
|
|
EP1083930B1
(en)
|
1998-06-05 |
2008-11-12 |
Nutrinia Limited |
Insulin supplemented infant formula
|
|
US6410508B1
(en)
|
1998-10-07 |
2002-06-25 |
Med College Georgia Res Inst |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
RU2218935C2
(ru)
|
1998-10-16 |
2003-12-20 |
Ново Нордиск А/С |
Стабильные концентрированные препаративные формы инсулина для доставки через легкие
|
|
CZ20011133A3
(cs)
|
1998-10-16 |
2001-08-15 |
Novo Nordisk A/S |
Insulinové přípravky pro plicní podávání obsahující menthol
|
|
US6211144B1
(en)
|
1998-10-16 |
2001-04-03 |
Novo Nordisk A/S |
Stable concentrated insulin preparations for pulmonary delivery
|
|
DE69914934T2
(de)
|
1998-11-18 |
2005-01-05 |
Novo Nordisk A/S |
Stabile, wässrige insulin-präparate ohne phenol und cresol
|
|
US6489292B1
(en)
|
1998-11-18 |
2002-12-03 |
Novo Nordisk A/S |
Stable aqueous insulin preparations without phenol and cresol
|
|
RU2242244C2
(ru)
|
1999-01-14 |
2004-12-20 |
Амилин Фармасьютикалз, Инк. |
Новые композиции агонистов эксендина и способы их введения
|
|
DE19908041A1
(de)
|
1999-02-24 |
2000-08-31 |
Hoecker Hartwig |
Kovalent verbrückte Insulindimere
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
JP2000247903A
(ja)
|
1999-03-01 |
2000-09-12 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
|
JP2007204498A
(ja)
|
1999-03-01 |
2007-08-16 |
Chugai Pharmaceut Co Ltd |
長期安定化製剤
|
|
US6227819B1
(en)
|
1999-03-29 |
2001-05-08 |
Walbro Corporation |
Fuel pumping assembly
|
|
US6271241B1
(en)
|
1999-04-02 |
2001-08-07 |
Neurogen Corporation |
Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
|
|
NZ514916A
(en)
|
1999-04-30 |
2004-06-25 |
Amylin Pharmaceuticals Inc |
Exendins and exendin agonists linked to polyethylene glycol polymers
|
|
AU754770B2
(en)
|
1999-05-17 |
2002-11-21 |
Conjuchem Biotechnologies Inc. |
Long lasting insulinotropic peptides
|
|
JP2003501404A
(ja)
|
1999-06-04 |
2003-01-14 |
デルルックス ファーマシューティカル コーポレイション |
薬剤の脱水粒子からなる製剤およびこれの調製方法
|
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
|
CA2369839A1
(en)
|
1999-06-25 |
2001-01-04 |
Minimed, Inc. |
Compositions of insulin and insulin-related peptide for treating diabetes
|
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
DE19930631A1
(de)
|
1999-07-02 |
2001-01-11 |
Clemens Micheler |
Spritzvorrichtung zur Injektion mindestens zweier flüssiger Therapeutika, insbesondere Insuline
|
|
EP1076066A1
(en)
|
1999-07-12 |
2001-02-14 |
Zealand Pharmaceuticals A/S |
Peptides for lowering blood glucose levels
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
IL148685A0
(en)
|
1999-09-21 |
2002-09-12 |
Rtp Pharma Inc |
Surface modified particulate compositions of biologically active substances
|
|
DE19947456A1
(de)
|
1999-10-02 |
2001-04-05 |
Aventis Pharma Gmbh |
C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
|
|
WO2001024814A1
(en)
|
1999-10-04 |
2001-04-12 |
Chiron Corporation |
Stabilized liquid polypeptide-containing pharmaceutical compositions
|
|
US6720001B2
(en)
|
1999-10-18 |
2004-04-13 |
Lipocine, Inc. |
Emulsion compositions for polyfunctional active ingredients
|
|
NZ518278A
(en)
|
1999-11-03 |
2004-10-29 |
Bristol Myers Squibb Co |
Pharmaceutical composition comprising a combination of metformin and glibenclamide
|
|
US7022674B2
(en)
|
1999-12-16 |
2006-04-04 |
Eli Lilly And Company |
Polypeptide compositions with improved stability
|
|
IL150129A0
(en)
|
1999-12-16 |
2002-12-01 |
Lilly Co Eli |
Polypeptide compositions with improved stability
|
|
EP1523993A1
(en)
|
1999-12-16 |
2005-04-20 |
Eli Lilly & Company |
Polypeptide compositions with improved stability
|
|
AU2353701A
(en)
|
2000-01-11 |
2001-07-24 |
Novo Nordisk A/S |
Transepithelial delivery of glp-1 derivatives
|
|
US20010012829A1
(en)
|
2000-01-11 |
2001-08-09 |
Keith Anderson |
Transepithelial delivery GLP-1 derivatives
|
|
WO2001052937A1
(en)
|
2000-01-24 |
2001-07-26 |
Medtronic Minimed, Inc. |
Mixed buffer system for stabilizing polypeptide formulations
|
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
|
AU2001264789A1
(en)
|
2000-06-08 |
2001-12-17 |
Eli Lilly And Company |
Protein powder for pulmonary delivery
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
AU2001280436A1
(en)
|
2000-07-12 |
2002-01-21 |
Eli Lilly And Company |
Process to increase protein stability
|
|
EP1326630B1
(en)
|
2000-09-18 |
2008-05-28 |
Sanos Bioscience A/S |
Use of glp-2 peptides
|
|
KR100508695B1
(ko)
|
2001-02-13 |
2005-08-17 |
한국과학기술연구원 |
인슐린의 경구투여용 제형과 그의 제조방법
|
|
US7060675B2
(en)
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
|
DE10108211A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
|
|
DE10108212A1
(de)
|
2001-02-20 |
2002-08-22 |
Aventis Pharma Gmbh |
Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
|
|
DE10108100A1
(de)
|
2001-02-20 |
2002-08-29 |
Aventis Pharma Gmbh |
Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse
|
|
AU2002248464A1
(en)
|
2001-02-21 |
2002-09-12 |
Medtronic Minimed, Inc. |
Stabilized insulin formulations
|
|
WO2002067868A2
(en)
|
2001-02-26 |
2002-09-06 |
Millennium Pharmaceuticals, Inc. |
Methods for the treatment of metabolic disorders, including obesity and diabetes
|
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
|
DE60233722D1
(de)
|
2001-04-02 |
2009-10-29 |
Novo Nordisk As |
Insulinvorstufen und verfahren zu deren herstellung
|
|
CN1160122C
(zh)
|
2001-04-20 |
2004-08-04 |
清华大学 |
一种制备口服胰岛素油相制剂的方法
|
|
US20030026872A1
(en)
|
2001-05-11 |
2003-02-06 |
The Procter & Gamble Co. |
Compositions having enhanced aqueous solubility and methods of their preparation
|
|
US6737401B2
(en)
|
2001-06-28 |
2004-05-18 |
Metronic Minimed, Inc. |
Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
|
|
AU2002318159A1
(en)
|
2001-06-29 |
2003-03-03 |
The Regents Of The University Of California |
Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
|
|
FR2827604B1
(fr)
|
2001-07-17 |
2003-09-19 |
Sanofi Synthelabo |
Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
|
|
CA2455963C
(en)
|
2001-07-31 |
2017-07-04 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Glp-1, exendin-4, peptide analogs and uses thereof
|
|
WO2003020201A2
(en)
|
2001-08-28 |
2003-03-13 |
Eli Lilly And Company |
Pre-mixes of glp-1 and basal insulin
|
|
US20050013867A1
(en)
|
2001-10-19 |
2005-01-20 |
Lehrman S. Russ |
Use of proton sequestering agents in drug formulations
|
|
US20050123509A1
(en)
|
2001-10-19 |
2005-06-09 |
Lehrman S. R. |
Modulating charge density to produce improvements in the characteristics of spray-dried proteins
|
|
WO2003044210A2
(en)
|
2001-11-19 |
2003-05-30 |
Novo Nordisk A/S |
Process for preparing insulin compounds
|
|
US20030170691A1
(en)
|
2001-12-19 |
2003-09-11 |
Millennium Pharmaceuticals, Inc. |
Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor
|
|
JP2005519041A
(ja)
|
2001-12-20 |
2005-06-30 |
イーライ・リリー・アンド・カンパニー |
長期作用を備えたインスリン分子
|
|
WO2003055512A1
(en)
|
2001-12-21 |
2003-07-10 |
Novo Nordisk Health Care Ag |
Liquid composition of factor vii polypeptides
|
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
|
WO2003066084A1
(en)
|
2002-02-07 |
2003-08-14 |
Novo Nordisk A/S |
Use of glp-1 compound for treatment of critically ill patients
|
|
US20100069293A1
(en)
|
2002-02-27 |
2010-03-18 |
Pharmain Corporation |
Polymeric carrier compositions for delivery of active agents, methods of making and using the same
|
|
TWI351278B
(en)
|
2002-03-01 |
2011-11-01 |
Nisshin Pharma Inc |
Agent for preventing and treating of liver disease
|
|
JP5599543B2
(ja)
|
2002-05-07 |
2014-10-01 |
ノヴォ ノルディスク アー／エス |
単量体インスリン及びアシル化インスリンを含む可溶性製剤
|
|
EP1506003A1
(en)
|
2002-05-07 |
2005-02-16 |
Novo Nordisk A/S |
Soluble formulations comprising insulin aspart and insulin detemir
|
|
US7115563B2
(en)
|
2002-05-29 |
2006-10-03 |
Insignion Holding Limited |
Composition and its therapeutic use
|
|
US20040022792A1
(en)
|
2002-06-17 |
2004-02-05 |
Ralph Klinke |
Method of stabilizing proteins at low pH
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
MXPA04012497A
(es)
|
2002-07-04 |
2005-07-14 |
Zealand Pharma As |
Glp-1 y metodos para tratar la diabetes.
|
|
DE10235168A1
(de)
|
2002-08-01 |
2004-02-12 |
Aventis Pharma Deutschland Gmbh |
Verfahren zur Reinigung von Preproinsulin
|
|
EP1558237A4
(en)
|
2002-09-27 |
2007-01-17 |
Martek Biosciences Corp |
IMPROVED GLYCEMIC REGULATION IN PREDIABETE AND / OR DIABETES TYPE II USING DOCOSAHEXAENOIC ACID
|
|
RU2376314C2
(ru)
|
2002-10-02 |
2009-12-20 |
Зилэнд Фарма А/С |
Стабилизированные соединения эксендина-4
|
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
ES2359720T3
(es)
|
2002-11-20 |
2011-05-26 |
Neuronova Ab |
Compuestos y métodos para aumentar la neurogénesis.
|
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
CN1413582A
(zh)
|
2002-11-29 |
2003-04-30 |
贵州圣济堂制药有限公司 |
盐酸二甲双胍肠溶片及其制备方法
|
|
EP1569682A2
(en)
|
2002-12-03 |
2005-09-07 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
|
GB0309154D0
(en)
|
2003-01-14 |
2003-05-28 |
Aventis Pharma Inc |
Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
|
|
GB0304822D0
(en)
|
2003-03-03 |
2003-04-09 |
Dca Internat Ltd |
Improvements in and relating to a pen-type injector
|
|
BRPI0408097A
(pt)
|
2003-03-04 |
2006-02-14 |
Technology Dev Company Ltd |
composição de insulina oral e processos para a produção e para o uso da mesma
|
|
JP2007523842A
(ja)
|
2003-03-11 |
2007-08-23 |
ノボ ノルディスク アクティーゼルスカブ |
酸安定化されたインスリンを含有する薬学的製剤
|
|
US20040186046A1
(en)
|
2003-03-17 |
2004-09-23 |
Pfizer Inc |
Treatment of type 1 diabetes with PDE5 inhibitors
|
|
US20060217290A1
(en)
|
2003-04-29 |
2006-09-28 |
Kohn Wayne D |
Insulin analogs having protracted time action
|
|
MXPA05013048A
(es)
|
2003-06-03 |
2006-03-02 |
Novo Nordisk As |
Composiciones peptodicas farmaceuticas estabilizadas.
|
|
DE10325567B4
(de)
|
2003-06-05 |
2008-03-13 |
Mavig Gmbh |
Strahlenschutzanordnung mit separierbarer Umhüllung
|
|
CA2542372A1
(en)
|
2003-08-29 |
2005-03-10 |
Centocor, Inc. |
Method of promoting graft survival with anti-tissue factor antibodies
|
|
WO2005021022A2
(en)
|
2003-09-01 |
2005-03-10 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
WO2005023291A2
(en)
|
2003-09-11 |
2005-03-17 |
Novo Nordisk A/S |
Use of glp1-agonists in the treatment of patients with type i diabetes
|
|
EP1667724A2
(en)
|
2003-09-19 |
2006-06-14 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
WO2005046716A1
(en)
|
2003-11-13 |
2005-05-26 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
US20050201978A1
(en)
|
2003-11-17 |
2005-09-15 |
Lipton James S. |
Tumor and infectious disease therapeutic compositions
|
|
JP2007515235A
(ja)
|
2003-12-22 |
2007-06-14 |
ノボ・ノルデイスク・エー／エス |
医薬液を保存するための、透明で、可撓性且つ不浸透性のプラスチック製容器
|
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
WO2005067898A2
(en)
|
2004-01-07 |
2005-07-28 |
Nektar Therapeutics |
Improved sustained release compositions for pulmonary administration of insulin
|
|
US20070027063A1
(en)
|
2004-01-12 |
2007-02-01 |
Mannkind Corporation |
Method of preserving the function of insulin-producing cells
|
|
US20080248999A1
(en)
|
2007-04-04 |
2008-10-09 |
Biodel Inc. |
Amylin formulations
|
|
US20080090753A1
(en)
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
|
KR20070004078A
(ko)
|
2004-03-31 |
2007-01-05 |
센토코 인코포레이티드 |
인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도
|
|
JP5000493B2
(ja)
|
2004-05-20 |
2012-08-15 |
ディアメディカ インコーポレイテッド |
インスリン抵抗性を治療するための製薬組成物、同製薬組成物の調製においてベタネコール及びｎ−アセチルシステインを使用する方法及び同製薬組成物を含むキット
|
|
BRPI0510527A
(pt)
|
2004-06-01 |
2007-10-30 |
Ares Trading Sa |
método de estabilização de proteìnas
|
|
BRPI0512535A
(pt)
|
2004-06-24 |
2008-03-25 |
Incyte Corp |
compostos de piperidinas n-substituìdas, suas composições e métodos de modulações
|
|
JP2008504249A
(ja)
|
2004-06-28 |
2008-02-14 |
ノボ ノルディスク アクティーゼルスカブ |
糖尿病を治療するための方法
|
|
KR20070039593A
(ko)
|
2004-07-21 |
2007-04-12 |
암브룩스, 인코포레이티드 |
비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
|
|
US20100048454A1
(en)
|
2004-08-03 |
2010-02-25 |
Emisphere Technologies, Inc. |
Antidiabetic oral insulin-biguanide combination
|
|
EP1778839B1
(en)
|
2004-08-13 |
2008-07-09 |
Roche Diagniostics GMBH |
C-terminal modification of polypeptides
|
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
US20060073213A1
(en)
|
2004-09-15 |
2006-04-06 |
Hotamisligil Gokhan S |
Reducing ER stress in the treatment of obesity and diabetes
|
|
WO2006029634A2
(en)
|
2004-09-17 |
2006-03-23 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and insulinotropic peptide
|
|
JP2006137678A
(ja)
|
2004-11-10 |
2006-06-01 |
Shionogi & Co Ltd |
インターロイキン−２組成物
|
|
CA2586771A1
(en)
|
2004-11-12 |
2006-05-18 |
Novo Nordisk A/S |
Stable formulations of insulinotropic peptides
|
|
ES2575984T3
(es)
|
2004-11-12 |
2016-07-04 |
Novo Nordisk A/S |
Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
|
|
DE102004058306A1
(de)
|
2004-12-01 |
2006-07-27 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
|
|
SE0402976L
(sv)
|
2004-12-03 |
2006-06-04 |
Mederio Ag |
Medicinsk produkt
|
|
KR20070090036A
(ko)
|
2004-12-22 |
2007-09-04 |
센토코 인코포레이티드 |
Ｇｌｐ-1 작용제, 조성물, 방법 및 용도
|
|
US7879361B2
(en)
|
2005-01-04 |
2011-02-01 |
Gp Medical, Inc. |
Nanoparticles for drug delivery
|
|
US20090142338A1
(en)
|
2005-03-04 |
2009-06-04 |
Curedm, Inc. |
Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
|
|
CA2602249C
(en)
|
2005-04-08 |
2012-07-10 |
Amylin Pharmaceuticals, Inc. |
Peptide and protein formulations with improved stability
|
|
WO2006125763A1
(en)
|
2005-05-25 |
2006-11-30 |
Novo Nordisk A/S |
Stabilized polypeptide formulations
|
|
US8546326B2
(en)
|
2005-06-06 |
2013-10-01 |
Camurus Ab |
Glp-1 analogue formulations
|
|
CN102036662B
(zh)
|
2005-06-27 |
2013-02-27 |
新树股份有限公司 |
利用肉豆蔻衣木脂素预防和治疗ppar介导的疾病的方法
|
|
EP1915334A2
(en)
|
2005-07-07 |
2008-04-30 |
Aditech Pharma AB |
Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
|
|
US20090239796A1
(en)
|
2005-08-19 |
2009-09-24 |
Amylin Pharmaceuticals, Inc. |
Methods for treating diabetes and reducing body weight
|
|
EP1937297A2
(en)
|
2005-09-08 |
2008-07-02 |
Gastrotech Pharma A/S |
Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
|
|
US7981635B2
(en)
|
2005-09-14 |
2011-07-19 |
Sanofi-Aventis Deutschland Gmbh |
Cleavage of precursors of insulins by a variant of trypsin
|
|
US8143217B2
(en)
|
2005-09-20 |
2012-03-27 |
Novartis Ag |
Use of DPP-IV inhibitor to reduce hypoglycemic events
|
|
EP1945142B1
(en)
|
2005-09-26 |
2013-12-25 |
Medtronic, Inc. |
Prosthetic cardiac and venous valves
|
|
DE102005046113A1
(de)
|
2005-09-27 |
2007-03-29 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
|
|
KR101105871B1
(ko)
|
2005-09-27 |
2012-01-16 |
주식회사 엘지생명과학 |
인 난포자극호르몬의 안정한 용액 제형
|
|
US8084420B2
(en)
|
2005-09-29 |
2011-12-27 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
|
ES2654520T3
(es)
|
2005-10-11 |
2018-02-14 |
Huntington Medical Research Institutes |
Agentes de formación de imágenes y métodos de uso de los mismos
|
|
PT1940243E
(pt)
|
2005-10-24 |
2011-10-17 |
Nestec Sa |
Formulação de fibras alimentares e método de administração
|
|
CA2630578C
(en)
|
2005-11-30 |
2014-04-15 |
Generex Pharmaceuticals Inc. |
Orally absorbed pharmaceutical formulation and method of administration
|
|
US20100029558A1
(en)
|
2005-12-06 |
2010-02-04 |
Bristow Cynthia L |
Alpha1 proteinase inhibitor peptides methods and use
|
|
WO2007075534A2
(en)
|
2005-12-16 |
2007-07-05 |
Nektar Therapeutics Al, Corporation |
Polymer conjugates of glp-1
|
|
US8178495B2
(en)
|
2008-06-27 |
2012-05-15 |
Duke University |
Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
|
|
EP2913056A1
(en)
|
2006-01-05 |
2015-09-02 |
The University of Utah Research Foundation |
Methods and compositions related to improving properties of pharmacological agents targeting nervous system
|
|
US8343914B2
(en)
|
2006-01-06 |
2013-01-01 |
Case Western Reserve University |
Fibrillation resistant proteins
|
|
WO2007082381A1
(en)
|
2006-01-20 |
2007-07-26 |
Diamedica Inc. |
Compositions containing (s)-bethanechol and their use in the treatment of insulin resistance, type 2 diabetes, glucose intolerance and related disorders
|
|
US20070191271A1
(en)
|
2006-02-10 |
2007-08-16 |
Dow Pharmaceutical Sciences |
Method for stabilizing polypeptides lacking methionine
|
|
WO2007095288A2
(en)
|
2006-02-13 |
2007-08-23 |
Nektar Therapeutics |
Methionine-containing protein or peptide compositions and methods of making and using
|
|
US7763582B2
(en)
|
2006-02-21 |
2010-07-27 |
University Of Medicine And Dentistry Of New Jersey |
Localized insulin delivery for bone healing
|
|
EP1996224B1
(en)
|
2006-03-15 |
2012-11-07 |
Novo Nordisk A/S |
Mixtures of amylin and insulin
|
|
TW200806317A
(en)
|
2006-03-20 |
2008-02-01 |
Wyeth Corp |
Methods for reducing protein aggregation
|
|
EP2004213A1
(en)
|
2006-04-03 |
2008-12-24 |
Novo Nordisk A/S |
Glp-1 peptide agonists
|
|
CN101454019A
(zh)
|
2006-04-12 |
2009-06-10 |
百达尔公司 |
速效和长效胰岛素联合制剂
|
|
US20100087365A1
(en)
|
2006-04-13 |
2010-04-08 |
Roland Cherif-Cheikh |
Pharmaceutical Compositions of Hglp-1, Exendin-4 and Analogs Thereof
|
|
WO2007140619A1
(en)
|
2006-06-08 |
2007-12-13 |
Diabecore Medical Inc. |
Derivatized insulin oligomers
|
|
DE102006031962A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
|
EP2076242B8
(en)
|
2006-07-27 |
2013-02-20 |
Nektar Therapeutics |
Aerosolizable formulation comprising insulin for pulmonary delivery
|
|
EP2057188B1
(en)
|
2006-08-17 |
2013-07-31 |
Amylin Pharmaceuticals, LLC |
Dpp-iv resistant gip hybrid polypeptides with selectable properties
|
|
WO2008023050A1
(en)
|
2006-08-25 |
2008-02-28 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
|
JP2010502670A
(ja)
|
2006-09-07 |
2010-01-28 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
真性糖尿病のための組合せ治療
|
|
WO2008034881A1
(en)
|
2006-09-22 |
2008-03-27 |
Novo Nordisk A/S |
Protease resistant insulin analogues
|
|
CA2683610C
(en)
|
2007-04-23 |
2013-01-08 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
|
WO2008145323A1
(en)
|
2007-05-31 |
2008-12-04 |
F. Hoffmann-La Roche Ag |
Pharmaceutical formulation for interferons
|
|
EP2155303A1
(de)
|
2007-06-14 |
2010-02-24 |
Sanofi-Aventis Deutschland GmbH |
Zweikammerkarpule
|
|
EP2167169B2
(de)
|
2007-06-14 |
2016-03-09 |
Sanofi-Aventis Deutschland GmbH |
Zweikammerkarpule mit aufsatz
|
|
EP2173407B1
(en)
|
2007-07-02 |
2020-02-19 |
Roche Diabetes Care GmbH |
A device for drug delivery
|
|
EP2578677A1
(en)
|
2007-08-09 |
2013-04-10 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
|
WO2009021955A1
(en)
|
2007-08-13 |
2009-02-19 |
Novo Nordisk A/S |
Rapid acting insulin analogues
|
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
GB0717388D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
|
|
GB0717399D0
(en)
|
2007-09-07 |
2007-10-17 |
Uutech Ltd |
Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
|
|
WO2009046850A1
(en)
|
2007-09-11 |
2009-04-16 |
Mondobiotech Laboratories Ag |
Cgrp as a therapeutic agent
|
|
US20090104210A1
(en)
|
2007-10-17 |
2009-04-23 |
Tota Michael R |
Peptide compounds for treating obesity and insulin resistance
|
|
CA2700662C
(en)
|
2007-11-01 |
2015-10-13 |
Merck Serono S.A. |
Lh liquid formulations
|
|
ES2543393T3
(es)
|
2007-11-08 |
2015-08-18 |
Novo Nordisk A/S |
Derivado de insulina
|
|
PT2597103T
(pt)
|
2007-11-16 |
2017-02-08 |
Novo Nordisk As |
Composições farmacêuticas contendo insulina e um péptido insulinotrófico
|
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
JP2011506442A
(ja)
|
2007-12-11 |
2011-03-03 |
コンジュケム バイオテクノロジーズ インコーポレイテッド |
インスリン分泌性ペプチド結合体の製剤
|
|
AU2009204309B2
(en)
|
2008-01-04 |
2012-11-22 |
Biodel, Inc. |
Insulin formulations for insulin release as a function of tissue glucose levels
|
|
ES2613152T3
(es)
|
2008-01-09 |
2017-05-22 |
Sanofi-Aventis Deutschland Gmbh |
Nuevos derivados de insulina con perfil tiempo/acción extremadamente retardado
|
|
CA2711752A1
(en)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Novel insulin derivatives having an extremely delayed time-action profile
|
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
ME01337B
(me)
|
2008-02-08 |
2013-12-20 |
Biogenerix Ag |
Tečni preparat fsh
|
|
WO2009102467A2
(en)
|
2008-02-13 |
2009-08-20 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
CN102015762B
(zh)
|
2008-02-19 |
2015-03-18 |
百康有限公司 |
获得纯化的生物活性异源蛋白的方法
|
|
TWI394580B
(zh)
|
2008-04-28 |
2013-05-01 |
Halozyme Inc |
超快起作用胰島素組成物
|
|
EP2288918A1
(en)
|
2008-05-23 |
2011-03-02 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist bioassays
|
|
TWI451876B
(zh)
|
2008-06-13 |
2014-09-11 |
Lilly Co Eli |
聚乙二醇化之離脯胰島素化合物
|
|
US7986407B2
(en)
|
2008-08-04 |
2011-07-26 |
Ondax, Inc. |
Method and apparatus using volume holographic wavelength blockers
|
|
EP2346551B1
(en)
|
2008-08-30 |
2020-12-16 |
Sanofi-Aventis Deutschland GmbH |
Cartridge and needle system therefor
|
|
US20100069292A1
(en)
|
2008-09-02 |
2010-03-18 |
Biodel, Inc. |
Insulin with a basal release profile
|
|
EP2684570A1
(en)
|
2008-09-10 |
2014-01-15 |
F. Hoffmann-La Roche AG |
Compositions and methods for the prevention of oxidative degradation of proteins
|
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
CN102281865B
(zh)
|
2008-10-15 |
2017-04-05 |
精达制药公司 |
高浓缩药物颗粒、制剂、混悬剂及其应用
|
|
ES2772731T3
(es)
|
2008-10-17 |
2020-07-08 |
Sanofi Aventis Deutschland |
Combinación de una insulina y un agonista de GLP-1
|
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
WO2010049488A1
(en)
|
2008-10-30 |
2010-05-06 |
Novo Nordisk A/S |
Treating diabetes melitus using insulin injections with less than daily injection frequency
|
|
JP2009091363A
(ja)
|
2008-11-21 |
2009-04-30 |
Asahi Kasei Pharma Kk |
Ｐｔｈの安定化水溶液注射剤
|
|
TWI466672B
(zh)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
小兒科病人糖尿病之治療
|
|
CA2750049C
(en)
|
2009-02-04 |
2021-02-23 |
Sanofi-Aventis Deutschland Gmbh |
Medical device and method for providing information for glycemic control
|
|
NZ594044A
(en)
|
2009-02-13 |
2014-08-29 |
Boehringer Ingelheim Int |
Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
|
|
US20120231022A1
(en)
|
2009-05-28 |
2012-09-13 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
|
JP2012532177A
(ja)
|
2009-07-06 |
2012-12-13 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
熱及び振動安定性インスリン製剤
|
|
JP5675799B2
(ja)
|
2009-07-06 |
2015-02-25 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
遅効性インスリン製剤
|
|
EP3202394A1
(de)
|
2009-07-06 |
2017-08-09 |
Sanofi-Aventis Deutschland GmbH |
Wässrige insulinzubereitungen enthaltend methionin
|
|
US8709400B2
(en)
|
2009-07-27 |
2014-04-29 |
Washington University |
Inducement of organogenetic tolerance for pancreatic xenotransplant
|
|
CA2769540C
(en)
|
2009-07-31 |
2017-08-15 |
Sanofi-Aventis Deutschland Gmbh |
Long acting insulin composition
|
|
WO2011017554A2
(en)
|
2009-08-07 |
2011-02-10 |
Mannkind Corporation |
Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
|
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
|
SI2498801T1
(en)
|
2009-11-13 |
2018-06-29 |
Sanofi-Aventis Deutschland Gmbh |
A pharmaceutical composition containing desPro36Exendin-4 (1-39) -Lys6-NH2 and methionine
|
|
SI2329848T2
(sl)
|
2009-11-13 |
2019-10-30 |
Sanofi Aventis Deutschland |
Liksisenatid kot dodana terapija pri inzulin glarginu in metforminu za zdravljenje diabetesa tipa 2
|
|
DK2498802T3
(en)
|
2009-11-13 |
2015-04-13 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
|
|
CA2685638C
(en)
|
2009-11-13 |
2017-02-28 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
|
US20110118180A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
|
PT2324853E
(pt)
|
2009-11-13 |
2015-11-30 |
Sanofi Aventis Deutschland |
Lixisenatida como adjuvante da metformina no tratamento de diabetes do tipo 2
|
|
US20110118178A1
(en)
|
2009-11-13 |
2011-05-19 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
|
|
WO2011075623A1
(en)
|
2009-12-18 |
2011-06-23 |
Latitude Pharmaceuticals, Inc. |
One - phase gel compos ition compri s ing phos pholi pids
|
|
EP2460527A1
(en)
|
2010-01-21 |
2012-06-06 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
US20130085101A1
(en)
|
2010-02-22 |
2013-04-04 |
Case Western Reserve University |
Long-acting insulin analogue preparations in soluble and crystalline forms
|
|
AR081066A1
(es)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
Conjugado de insulina donde se usa un fragmento de inmunoglobulina
|
|
AR080884A1
(es)
|
2010-04-14 |
2012-05-16 |
Sanofi Aventis |
Conjugados de insulina-sirna
|
|
US8637458B2
(en)
|
2010-05-12 |
2014-01-28 |
Biodel Inc. |
Insulin with a stable basal release profile
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
WO2011144674A2
(en)
|
2010-05-20 |
2011-11-24 |
Sanofi-Aventis Deutschland Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
|
|
EP2389945A1
(en)
*
|
2010-05-28 |
2011-11-30 |
Sanofi-Aventis Deutschland GmbH |
Pharmaceutical composition comprising AVE0010 and insulin glargine
|
|
WO2011160066A1
(en)
|
2010-06-17 |
2011-12-22 |
Regents Of The University Of Minnesota |
Production of insulin producing cells
|
|
US8532933B2
(en)
|
2010-06-18 |
2013-09-10 |
Roche Diagnostics Operations, Inc. |
Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
|
|
US20130137645A1
(en)
|
2010-07-19 |
2013-05-30 |
Mary S. Rosendahl |
Modified peptides and proteins
|
|
HUE031181T2
(en)
|
2010-08-30 |
2017-06-28 |
Sanofi Aventis Deutschland |
Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
|
|
MX366314B
(es)
|
2010-10-27 |
2019-07-05 |
Novo Nordisk As |
Uso de derivados de insulina por inyecciones con intervalos variables.
|
|
WO2012065996A1
(en)
|
2010-11-15 |
2012-05-24 |
Sanofi-Aventis Deutschland Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
|
|
WO2012066086A1
(en)
|
2010-11-17 |
2012-05-24 |
Sanofi-Aventis Deutschland Gmbh |
PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
|
|
US20130331320A1
(en)
|
2010-12-14 |
2013-12-12 |
Novo Nordisk A/S |
Fast-acting insulin in combination with long-acting insulin
|
|
US20130085102A1
(en)
|
2011-02-02 |
2013-04-04 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycemia in diabetes mellitus type 2 patients
|
|
TR201909840T4
(tr)
|
2011-03-11 |
2019-07-22 |
Beth Israel Deaconess Medical Ct Inc |
Anti-CD40 antikorları ve kullanımları.
|
|
US20120277147A1
(en)
|
2011-03-29 |
2012-11-01 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
|
US20130040878A1
(en)
|
2011-05-13 |
2013-02-14 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in the treatment of diabetes type 2 patients
|
|
US8735349B2
(en)
|
2011-05-13 |
2014-05-27 |
Sanofi-Aventis Deutschland Gmbh |
Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
|
|
US9821032B2
(en)
*
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
CA2835259C
(en)
|
2011-05-13 |
2020-01-07 |
Sanofi-Aventis Deutschland Gmbh |
Lixisenatide and metformin for treatment of diabetes type 2
|
|
CN103906528A
(zh)
|
2011-06-24 |
2014-07-02 |
安米林药品有限责任公司 |
用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
|
|
DK2750699T3
(en)
|
2011-08-29 |
2015-10-26 |
Sanofi Aventis Deutschland |
A pharmaceutical combination for use in glycemic control in diabetes type 2 patients
|
|
AR087744A1
(es)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
|
|
WO2013050378A1
(en)
|
2011-10-04 |
2013-04-11 |
Sanofi-Aventis Deutschland Gmbh |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
|
HRP20160171T1
(hr)
|
2011-10-04 |
2016-03-11 |
Sanofi-Aventis Deutschland Gmbh |
Liksisenatid za uporabu u lijeäśenju stenoze i/ili opstrukcije u sustavu kanala gušteraäśe
|
|
MX359329B
(es)
|
2011-10-28 |
2018-09-25 |
Sanofi Aventis Deutschland |
Una combinación farmacéutica para usarse en el tratamiento de un paciente que padece diabetes tipo 2.
|
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
US9522235B2
(en)
|
2012-05-22 |
2016-12-20 |
Kaleo, Inc. |
Devices and methods for delivering medicaments from a multi-chamber container
|
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
TWI780236B
(zh)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
|
WO2014131815A1
(en)
|
2013-03-01 |
2014-09-04 |
Fundació Hospital Universitari Vall D'hebron - Institut De Recerca |
Peptides for use in the topical treatment of retinal neurodegenerative disesases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
|
|
GB201303771D0
(en)
|
2013-03-04 |
2013-04-17 |
Midatech Ltd |
Nanoparticles peptide compositions
|
|
EP3010530B1
(en)
|
2013-06-17 |
2018-12-26 |
Sanofi-Aventis Deutschland GmbH |
Insulin glargine/lixisenatide fixed ratio formulation
|
|
TW201605489A
(zh)
|
2013-10-25 |
2016-02-16 |
賽諾菲公司 |
賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物
|
|
LT3229828T
(lt)
|
2014-12-12 |
2023-06-12 |
Sanofi-Aventis Deutschland Gmbh |
Insulino glargino/liksisenatido fiksuoto santykio kompozicija
|
|
US20160235818A1
(en)
|
2015-01-16 |
2016-08-18 |
Sanofi-Aventis Deutschland Gmbh |
Treatment of Pediatric Type 2 Diabetes Mellitus Patients
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|
|
US10905707B2
(en)
|
2017-11-10 |
2021-02-02 |
University Of Massachusetts |
Compositions and methods for the treatment of expanded repeat-associated disorders
|